



Investor News

Bayer Evaluating Next Steps for Repinotan Compound

Compound for new type of stroke treatment did not meet the anticipated clinical benefit

Leverkusen / December 23, 2004 – Bayer HealthCare will be ending its current development program for Repinotan, a substance for the treatment of acute ischemic stroke patients. A recently completed Phase IIb clinical trial with the Repinotan compound did not fulfil expectations. Repinotan, which belongs to the neuroprotectant class of drugs, did not meet the primary endpoints of the study and the anticipated clinical benefit could not be demonstrated in this very challenging clinical research area.

Bayer HealthCare continues to develop innovative treatments that address unmet patient needs. While ending the development with Repinotan in stroke, Bayer is still considering other options for the future of this compound.

Bayer HealthCare AG, a subgroup of Bayer AG with sales of approximately 8.9 billion Euro in 2003, is one of the world's leading, innovative companies in the health care and medical products industry. The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. More than 34,000 people are employed by Bayer HealthCare worldwide. Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease.

Leverkusen, December 23, 2004

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)

Dr. Juergen Beunink (+49-214-30-65742)

Peter Dahlhoff (+49-214-30-33022)

Ute Krippendorf (+49-214-30-33021)

Ilia Kürten (+49-214-30-35426)

Judith Nestmann (+49-214-30-66836)

Forward-looking statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.